Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
like that as soon as you sell BMSN.. the FDA approval news comes out.. that would suck..
BMSN....$$$$ you know you can block people ...
GO BMSN
In closing, this is a very exciting time for Amarantus. We just completed our first institutional capital raise and have attracted Big Pharma talent to our Advisory Board. We have data coming shortly on our MANF Parkinson’s program and expect additional corporate milestones will be reached in the coming weeks. As we achieve these milestones, we believe we will be in a good position to up-list to a national exchange. Most importantly, we are looking to bring hope to millions of patients and their families who suffer from the debilitating diseases MANF has the potential to treat. We strongly believe this strategy will build long-term shareholder value.
I see a few familiar Whales in this , the next major Break out stock of 2013. VOIS is not a secret anymore. Was referred to this GEM from a few different avenues. Interesting how excited they were all about the huge potential here. Took a nice position and ready to Fly
GL2ALL
LONG
All i needed to do. was to
Place a bid, buy. And this took off. Lol. CPSZ. Great potential. Can't wait for PR's to come out.
“Cashless Jail” Companies Expand Partnership CPSZ
http://www.correctionalnews.com/articles/2011/06/21/cashless-jail-companies-expand-partnership
Everyone needs to google EZcard or EZCard city approval Here you will find city's where they are bringing CPSZ before the city officials. CPSZ can't file an 8K with intent to approach a customer. The 8K comes AFTER a city approves EZcard. They are ALL over the U.S. right now. Tons of 8K's coming after approvals are granted by city's.
CPSZ looks like an interesting play.... Bouncing
the indication of Aplastic Anemia has already been qualified as Orphan Status by the FDA
http://www.globes.co.il/serveen/globes/docview.asp?did=1000824194&fid=1725
If it does get FDA approval... it is already an Indication that is approved Orphan Status .
Thats your opinion. I agree with the other poster. Nothing neutral about it. They terminated the LOI. No other company would want to negotiate with a company that has intent to sign the same or similar deal with a competing company.
The current IND application is the same application for an Indication that already been designated Orphan Status by the FDA is my point..
see IND app... FORM FDA-1571 box 7
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/default.htm
And Aplastic Anemia has already been designated Orphan Status.
Also check here from time to time... it should show up one of these days IMO
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
it will only appear there once it is approved to proceed..
you do not have to submit a separate IND, the FDA can Designate Orphan status to the Initial IND
Lets not forget that BMSN - IND app. is for Aplastic Anemia which is considered an Orphan Drug Designation and the FDA can take up to 60 days to review. if it takes longer its not a negative IMO.. It may well be even more positive than we all can imagine.
Is US Government small?
Group of AMBS investors
Buying in the AM.. was referred to this Company MCET by a group who are going to pounce on this one also..
GL2ALL the Longs..
you make joke funny... BMSN FDA Ok on the Clock..
CEO of the Year.. cover of forbes saving lives with IND's
any new videos?
If they begin the trial then it is approved...this is human clinical trial you think the FDA will let you commence human trial if it is not approved?
Here is an informative PDF .. on IND Review Process ... if you actually try to look for it you can find what you are asking about.
BMSN is on the clock
https://secure.emmes.com/pactweb/.../cber101032204jf.pdf
and nice new profile you have...
read evidence yourself BMSN in on the Clock.
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/default.htm
I think you are back tracking a bit on time frames now.. but I can wait 6 months... I think FDA will let trial begin sooner than you say due to the potential of saving lives.. but we are all just assuming here right?
we shall see...
GL2ALL & BMSN
Untreated aplastic anemia leads to rapid death, typically within six months.
Was ACT* trying to treat a life threatening disease?
doesn't this make a big difference ? in IND's approval rates..
Just saying
BMSM
The shake off of the weak hands worked. BMSN is now primed for next run. Seen it happen too many times.
GL2ALL
The shake off of the weak hands worked. BMSN is now primed for next run. Seen it happen too many times.
GL2ALL
BUYER PREPARE for realizing this may be the most undervalued company to invest in for 2013 the Inevitable upside is Incredible
Don't be swayed read the DD up above and see how LEGIT AMBS is and how well run & organized it has displayed.
Just Check the resumes of its board of advisors :
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
Dr. Mark Benedyk
Corporate Advisor
Dr. Benedyk, is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Among other things, in this role, he is a Strategic Advisory Board member to a clinical-stage neuropsychiatry specialty care company, is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University’s Graduate School of Business, and the University of Virginia Darden School of Business.
Dr. Owen Garrick
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Clinton Allen
Corporate Advisor
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
http://ih.advfn.com/p.php?pid=nmona&article=56209644
advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies
read this impressive Info.. not your average penny stock here.. AMBS Has a plan and its in motion.. Best of all it has the patents on the "FIRST IN CLASS" Molecule called MANF the new standard!!!!
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
Recruiting from other boards. To bring down BMSN. Because you know you need major help. Lol. FDA approval has you staying up late
Funniest thing ive seen on here. Thanks.
US Department of Defense introduces AMBS to Banyan Biomarkers.
1000 % Legitimacy
Even uncle Sam knows what they are on to.
$$$$$$$
A Cure for Parkinson's Disease
Watch this Video.. AMBS is on the road to LEGENDARY Status
Building value from a solid foundation
The data the Company released recently related to our MANF program in Parkinson’s disease is groundbreaking and first of its kind in the Parkinson’s space. Our Chief Scientific Officer, Dr. John Commissiong, presented the data at the OneMedForum 2013 Healthcare Conference, and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies.
the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.
source:
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
a blockbuster drug $AMBS$
Dr. Rubinfeld will assist management in positioning the Company’s development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson’s, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company’s new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug.”
Enough Said...
U.S. Department of Defense introduced Amarantus to Banyan Biomarkers
100 % LEGITIMACY HERE
The US Government does not supports Scams.. Know what you own!
http://www.drugdiscoverynews.com/index.php?newsarticle=5717
MANF: has potent curative properties that stops/or reverses the
progression of PD; improves behavior, the fundamental treatment goal of PD therapeutics;
The acquisition of Neurodegenerative Diagnostic’s intellectual property has also significantly
leveraged Amarantus. In this transaction Amarantus took ownership of 20 pending patent
applications covering a variety of biomarkers and assays related to the treatment of various
neurological disorders including Parkinson's, Alzheimer's, and ALS, as well as patent applications
related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. These
technologies provide an invaluable addition to Amarantus’ intellectual property estate, which
integrates seamlessly with and supports the company’s therapeutic platform.
Amarantus is currently preparing Phase 2 clinical trials for the acquired NuroPro Parkinson’s
Disease blood test, which serves as a diagnostic for early detection of PD
Are you ready for AMBS PPS Launch into the Stratosphere?
next week will be exciting.. AMBS will make us proud